Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-directed RNA polymerase III subunit K (POLR3K)
- Target
- POLR3K
- Molecular classification
- Enzyme, DNA-directed RNA polymerase subunit, Transcription factor (as a function within the multi-protein RNA polymerase III complex), Other: Polymerase complex component
01
Overview
DNA-directed RNA polymerase III subunit K (POLR3K) is a small, essential protein component of the multi-subunit RNA polymerase III enzyme complex, which synthesizes small non-coding RNAs (including tRNA, 5S rRNA, and U6 snRNA) in eukaryotic cells[1][2][5][7]. POLR3K is critical for proper transcription fidelity, termination, and Pol III’s ability to sense and limit infections by intracellular bacteria and DNA viruses through the innate immune response, acting as a sensor for non-self double-stranded DNA and RNA and inducing type I interferon signaling[1][8]. Genetic mutations in POLR3K have been linked to certain neurodegenerative diseases, such as hypomyelinating leukodystrophy[1][3][9]. No drugs currently target POLR3K directly, likely due to its essential cellular role and broad transcriptional functions.
- Other names
- RNA polymerase III subunit KRPC10RPC11C11POLR3KPolymerase (RNA) III (DNA directed) polypeptide K, 12.3 kDaRNA polymerase III 12.5 kDa subunitRNA polymerase III subunit C10RNA polymerase III subunit C11DNA-directed RNA polymerase III subunit RPC10DNA-directed RNA polymerase III subunit K
02
Mechanism of action
null
03
Biological functions
Transcription of small non-coding RNAs (tRNA, 5S rRNA, U6 snRNA)RNA synthesisInnate immune response (nuclear and cytosolic DNA sensing; induction of type I interferon response via RIG-I pathway against viral RNAs)Monitoring transcription fidelity, pausing and termination of Pol IIICleaving mis-incorporated ribonucleotides and restarting transcription upon errors
04
Disease associations
Hypomyelinating leukodystrophy (multiple subtypes)Neurodegenerative diseaseInfection (by regulating immune detection of pathogens)Other: Hematopoietic stem cell homeostasis (noted in animal models)
05
Safety considerations
Genetic loss-of-function or mutation can cause severe, early-onset neurodevelopmental disorders, especially hypomyelinating leukodystrophyDue to its essential housekeeping role in RNA synthesis, targeting POLR3K with drugs may carry broad safety risks for cell viability and general transcription, particularly in the central nervous systemPseudogenes may complicate genetic analyses
06
Biomarkers
Genetic variants in POLR3K can serve as biomarkers for diagnosis and patient selection in leukodystrophy and related neurodegenerative disorders. (No widely adopted biomarker in clinical use identified; genetic testing used for rare disease diagnosis.)
Beyond the preview
Go deeper on DNA-directed RNA polymerase III subunit K (POLR3K).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA-directed RNA polymerase III subunit K (POLR3K).